tradit
technolog
analysi
dna
mrna
protein
analyz
paramet
time
therefor
limit
throughput
larg
number
paramet
need
identifi
implement
dna
protein
microarray
led
tremend
acceler
biomark
discoveri
ultim
goal
identifi
set
diseasespecif
biomark
combin
robust
screen
technolog
approach
allow
clinician
screen
patient
prescrib
particular
drug
order
exclud
potenti
advers
effect
determin
suitabl
dose
besid
make
improv
new
technolog
research
must
also
identifi
valid
appropri
set
biomark
subsequ
integr
healthcar
servic
fig
summar
work
flow
biomark
discoveri
protein
microarray
anticip
applic
protein
assay
person
medicin
protein
microarray
recent
demonstr
huge
potenti
field
biomark
discoveri
rppm
use
identifi
biomark
candid
cancer
patient
show
chang
concentr
correl
state
progress
diseas
sandwich
immunoassay
prove
excel
method
accur
quantifi
biomark
candid
multiplex
easili
achiev
beadbas
technolog
highthroughput
multiplex
immunoassay
perfectli
suit
screen
cancer
biomark
larg
cohort
clinic
sampl
provid
insight
detail
product
plasma
tissu
protein
therebi
furnish
detail
inform
patient
physiolog
patholog
condit
use
sophist
bioinformat
tool
allow
identif
biomark
pattern
use
diagnost
purpos
data
set
gener
multiplex
immunoassay
integr
multivari
diagnost
model
algorithm
knearest
neighbor
logist
regress
analys
markedli
improv
diagnost
sensit
specif
cancer
diagnost
compar
previous
possibl
singleparamet
analysi
recent
visintin
et
al
use
multiplex
sandwich
immunoassay
leptin
prolactin
osteopontin
insulinlik
growth
factor
ii
macrophag
inhibitori
factor
cancer
antigen
screen
plasma
patient
ovarian
cancer
use
panel
screen
sampl
healthi
control
patient
newli
diagnos
ovarian
cancer
screen
achiev
diagnost
sensit
diagnost
specif
amonkar
et
al
identifi
panel
ca
solubl
epiderm
growth
factor
receptor
egfr
creactiv
protein
myoglobin
apolipoprotein
apo
apo
ciii
macrophag
inhibitori
protein
tenascin
c
use
distinguish
plasma
sampl
patient
ovarian
cancer
sampl
patient
benign
condit
screen
patient
control
reveal
achiev
diagnost
sensit
specif
high
contrast
singl
paramet
current
achiev
diagnost
sensit
earli
stage
diseas
candid
biomark
panel
requir
valid
larger
patient
cohort
howev
reliabl
use
routin
clinic
diagnost
increas
list
biomark
candid
show
protein
microarray
huge
potenti
contribut
develop
individu
medic
therapi
knowledg
gener
protein
microarray
help
clinician
adapt
therapi
individu
patient
requir
also
help
minim
risk
advers
effect
caus
incorrectli
chosen
drug
drug
dose
datadriven
approach
involv
proteomewid
analysi
identifi
correl
protein
concentr
particular
diseas
state
approach
unbias
assumpt
made
protein
might
involv
diseas
process
howev
protein
microarray
approach
develop
global
analysi
protein
concentr
still
infanc
combin
current
antibodi
array
direct
samplelabel
strategi
allow
analysi
limit
number
paramet
despit
effort
made
recombin
antibodi
technolog
classic
antibodi
gener
highqual
antibodi
direct
everi
singl
protein
interest
still
avail
nevertheless
highthroughput
techniqu
protein
analysi
use
gener
wholeproteom
array
consist
thousand
recombin
protein
highdens
protein
microarray
datadriven
approach
enabl
identif
new
autoantibodi
specif
varieti
diseas
hudson
et
al
use
protein
microarray
contain
human
protein
identifi
autoantibodi
set
capabl
recogn
antigen
sera
patient
ovarian
cancer
four
antigen
confirm
immunoblot
tissu
microarray
analys
research
found
lamin
ac
structurespecif
recognit
protein
ralbind
protein
produc
larger
quantiti
cancer
tissu
control
tissu
furthermor
diagnost
specif
sensit
combin
use
lamin
ac
perform
better
tumor
marker
alon
identifi
ovarian
cancer
approach
use
assess
immun
respons
pathogen
protein
zhu
et
al
gener
coronaviru
protein
microarray
contain
purifi
protein
sever
acut
respiratori
syndrom
sar
coronaviru
addit
coronavirus
aim
monitor
immun
respons
patient
infect
sar
approxim
serum
sampl
canadian
sar
outbreak
screen
sampl
includ
confirm
sar
coronaviru
case
patient
respiratori
ill
asymptomat
healthcar
worker
bioinformat
data
analysi
allow
classif
sera
accuraci
diagnost
sensit
diagnost
specif
studi
demonstr
well
protein
microarray
use
largescal
identif
virusspecif
antibodi
sera
schmid
et
al
gener
protein
microarray
consist
protein
vaccinia
viru
proteom
screen
sera
obtain
vaccin
individu
n
nonvaccin
individu
n
reveal
primari
antibodi
respons
individu
vaccinia
protein
vari
individu
individu
wherea
total
number
protein
recogn
antibodi
slightli
alter
second
vaccin
data
set
prove
protein
microarray
could
measur
humor
immun
respons
vaccin
provid
straightforward
approach
evalu
newli
develop
vaccin
nodular
thyroid
diseas
affect
individu
year
old
character
presenc
singl
multipl
nodul
within
thyroid
gland
thyroid
nodul
harm
cancer
thyroid
cancer
diagnos
treatment
begin
soon
possibl
fineneedl
biopsi
standard
diagnost
method
result
gener
biopsi
approach
satisfactori
linkov
et
al
use
beadbas
xmap
technolog
identifi
plasma
pattern
cytokin
chemokin
growth
factor
correl
benign
malign
thyroid
condit
univari
analysi
reveal
factor
epitheli
growth
factor
egf
hepatocyt
growth
factor
hgf
rant
regul
upon
activ
normal
texpress
presum
secret
enabl
individu
thyroid
diseas
distinguish
control
group
multivari
analysi
reveal
panel
paramet
hgf
monocyteinduc
interferon
discrimin
benign
malign
diseas
state
area
roc
curv
ci
result
demonstr
protein
array
defin
panel
plasmaserum
biomark
promis
tool
support
diagnosi
nodular
thyroid
diseas
sauer
et
al
use
protein
array
profil
fineneedl
biopsi
breast
cancer
patient
identifi
panel
biomark
specif
subgroup
breast
cancer
patient
lysat
prepar
largecor
needl
biopsi
invas
breast
carcinoma
analyz
beadbas
immunoassay
overal
aim
evalu
product
preselect
protein
result
reveal
profil
protein
tumor
fibroblast
growth
factor
fa
fa
ligand
tissu
inhibitor
metalloproteinas
rant
differ
consider
patient
group
without
axillari
lymph
node
metastasi
kim
et
al
use
similar
approach
distinguish
breast
cancer
patient
healthi
volunt
thirtyf
analyt
select
previous
screen
plasma
sampl
obtain
patient
variou
type
cancer
three
biomark
egf
solubl
ligand
identifi
increas
concentr
plasma
sampl
breast
cancer
group
six
biomark
show
decreas
plasma
concentr
high
molecular
weight
kininogen
apo
solubl
vascular
cell
adhes
molecul
plasminogen
activ
inhibitor
vitamin
protein
vitronectin
also
identifi
differ
algorithm
use
gener
diagnost
model
allow
breast
cancer
patient
discrimin
healthi
control
high
level
diagnost
accuraci
random
forest
analysi
support
vector
machin
analysi
linear
discrimin
analysi
huge
demand
identif
sepsisspecif
biomark
reflect
state
sever
inflammatori
diseas
bozza
et
al
use
miniatur
sandwich
immunoassay
evalu
predict
valu
cytokin
product
pattern
sepsi
time
cours
found
cytokin
concentr
increas
sever
inflamm
organ
dysfunct
increas
regard
sever
organ
dysfunct
concentr
evalu
cytokin
monocyt
chemoattract
protein
measur
day
correl
significantli
sequenti
organ
failur
assess
score
increas
plasma
concentr
granulocyt
colonystimul
factor
within
first
h
correl
organ
dysfunct
fail
recov
day
concentr
cytokin
granulocyt
colonystimul
factor
allow
predict
earli
mortal
identifi
serum
biomark
earli
late
inflammatori
bowel
diseas
ibd
torrenc
et
al
use
mous
model
mice
ibd
trigger
infect
helicobact
bili
multianalyt
profil
data
reveal
increas
plasma
protein
interferon
protein
lymphotactin
earlystag
ibd
eleven
protein
haptoglobin
matrix
metalloproteinas
fibrinogen
iga
apo
display
higher
concentr
late
stage
diseas
concentr
biomark
except
apo
correl
histopatholog
score
appropri
antibiot
treatment
improv
clinic
sign
ibd
led
decreas
mean
plasma
concentr
mani
biomark
ibd
anim
model
seem
suitabl
identifi
noninvas
biomark
monitor
ibd
progress
time
increas
understand
ibd
pathogenesi
major
prerequisit
develop
new
therapi
observ
anim
model
need
confirm
human
ibd
plasma
sampl
howev
definit
statement
made
suitabl
biomark
twenti
forti
percent
rheumatoid
arthriti
patient
respond
treatment
tumor
necrosi
factor
agent
etanercept
inappropri
treatment
costli
also
sever
side
effect
patient
therefor
identif
biomark
predict
clinic
respons
necrosi
factor
treatment
would
extrem
use
panel
cytokin
product
plasma
may
enabl
discrimin
respond
nonrespond
fabr
et
al
profil
plasma
cytokin
rheumatoid
arthriti
patient
undergo
etanercept
therapi
evid
biochip
array
randox
laboratori
use
measur
proinflammatori
antiinflammatori
cytokin
serum
sampl
collect
day
research
found
high
plasma
concentr
egf
associ
respons
etanercept
addit
combin
creactiv
protein
egf
prove
good
way
predict
effect
etanercept
treatment
month
diagnost
sensit
diagnost
specif
allen
et
al
observ
plasma
concentr
nuclear
factor
cytokin
growth
factor
growthregul
oncogen
vascular
endotheli
growth
factor
hgf
chang
patient
head
neck
squamou
cell
carcinoma
treat
chemotherapi
radiotherapi
plasma
paramet
quantit
analyz
sampl
patient
diagnosi
stage
iiiiv
oropharyng
carcinoma
discov
whether
plasma
paramet
protein
correl
treatment
respons
relaps
surviv
patient
treat
combin
chemotherapi
radiotherapi
relationship
cytokin
plasma
concentr
surviv
rate
investig
cox
proport
hazard
model
kaplanmei
surviv
analysi
detail
analysi
data
reveal
concentr
cytokin
correl
respons
therapi
poorer
causespecif
surviv
histori
nonsmok
higher
vascular
endotheli
growth
factor
concentr
also
correl
increas
surviv
rate
approach
envis
extend
cancer
poor
predict
outcom
monitor
longitudin
chang
cytokin
concentr
complement
inform
provid
clinic
monitor
imag
approach
kinas
interest
group
molecular
target
cancer
treatment
involv
among
thing
regul
cell
prolifer
differenti
systemat
analysi
signal
protein
sampl
individu
tumor
may
reveal
multipl
caus
player
cancer
progress
laser
captur
microdissect
use
resolv
problem
tissu
heterogen
enabl
isol
pure
tumor
cell
tissu
section
wulfkuhl
et
al
use
rppm
combin
laser
captur
microdissect
technolog
carri
systemat
analysi
cellular
signal
breast
cancer
tissu
metastat
lesion
twentyf
surgic
sampl
human
breast
cancer
screen
presenc
signal
molecul
possibl
defin
subgroup
sampl
primari
breast
tumor
metastat
lesion
protein
product
degre
phosphoryl
basi
pathwayspecif
signal
profil
egfr
famili
signal
aktmtor
pathway
activ
ckitabl
growth
factor
signal
erk
pathway
activ
author
propos
detail
character
signal
activ
huge
potenti
respect
design
patienttailor
therapeut
regimen
similar
approach
sheehan
et
al
profil
signal
activ
epitheli
stromal
compart
colon
carcinoma
author
infer
product
pattern
signal
molecul
coordin
cross
talk
exist
epithelium
stroma
cancer
suggest
transit
cross
talk
could
produc
therapyresist
tumor
epithelium
protein
find
could
therapeut
implic
treatment
colon
cancer
system
biolog
interdisciplinari
research
area
focus
systemat
studi
complex
interact
biolog
system
develop
mechanist
model
predict
behavior
dynam
system
compar
reductionist
approach
studi
smaller
spatial
scale
organiz
unit
understand
natur
complex
system
system
approach
base
integr
larg
genom
proteom
data
set
combin
broad
biolog
knowledg
comput
techniqu
larg
number
paramet
variabl
constraint
cellular
network
requir
use
numer
comput
techniqu
effort
made
system
biolog
approach
aim
gain
detail
insight
factor
live
cell
chang
occur
diseas
progress
protein
microarray
prove
one
largescal
measur
method
capabl
deliv
experiment
data
set
quantiti
requir
comput
approach
knickerbock
et
al
analyz
earli
mortal
patient
undergo
kidney
dialysi
research
appli
protein
microarray
quantifi
set
plasma
paramet
patient
sampl
combin
data
set
clinic
variabl
bodi
mass
index
diastol
blood
pressur
underli
diseas
method
vascular
access
author
abl
predict
earli
mortal
patient
undergo
kidney
dialysi
molecular
marker
combin
clinic
variabl
system
analysi
kind
enabl
individu
prognosi
support
clinician
choic
treatment
regimen
best
suit
individu
patient
within
last
decad
proteom
technolog
led
identif
huge
number
biomark
candid
howev
current
limit
valid
biomark
candid
success
valid
marker
includ
carcinoembryon
antigen
prostatespecif
antigen
numer
aspect
valid
process
need
improv
current
highoutput
technolog
use
discoveri
biomark
lowthroughput
method
therefor
novel
technolog
higher
throughput
higher
analyt
sensit
requir
technolog
must
also
take
account
fact
small
quantiti
sampl
typic
avail
particularli
case
clinic
sampl
protein
microarray
prove
excel
approach
biomarkervalid
studi
last
year
differ
autom
concept
develop
protein
array
one
advanc
format
beadbas
system
differ
compani
develop
autom
system
addit
planar
protein
microarray
adapt
microtit
plate
format
allow
microarray
process
standard
pipet
robot
multichannel
pipett
sever
diagnost
compani
develop
protein
technolog
platform
randox
evid
biochip
system
impact
profession
diagnost
platform
roch
diagnost
major
challeng
biomark
valid
avail
highqual
captur
molecul
eg
antibodi
despit
tremend
effort
develop
new
method
produc
highqual
captur
molecul
aptam
recombin
antibodi
potenti
valu
biomark
valid
still
need
demonstr
protein
microarray
excel
suit
diagnost
purpos
sever
diagnost
protein
microarray
product
clear
us
food
drug
administr
fda
cemark
use
eu
diagnosi
autoimmun
diseas
focu
protein
microarray
includ
athena
test
system
zeu
scientif
exclus
market
inver
medic
profession
diagnost
system
biorad
laboratori
immuno
solidphas
allergen
chip
vbc
genom
bioscienc
research
quanta
anca
profil
inova
diagnost
athena
multilyt
anca
test
system
perform
multipl
assay
simultan
singl
sampl
singl
well
perform
qualit
semiquantit
detect
iggclass
antibodi
separ
antineutrophil
cytoplasm
antibodi
anca
antigen
myeloperoxidas
oroteinas
intent
aid
diagnosi
number
autoimmun
vasculit
disord
character
increas
concentr
anca
compani
athena
ana
test
system
simultan
perform
antinuclear
antibodi
screen
reflex
test
specif
autoantibodi
ssa
ssb
sm
rnp
dsdna
centromer
b
histon
singl
well
focu
diagnost
develop
serolog
test
igg
test
kit
plexu
ebv
multianalyt
diagnost
serolog
test
kit
diagnosi
infecti
diseas
fda
clear
test
respect
plexu
herpeselect
igg
test
kit
first
multiplex
typespecif
herp
simplex
viru
serolog
test
use
luminex
xmap
technolog
detect
antibodi
herp
simplex
viru
type
assist
clinician
choos
appropri
treatment
counsel
second
test
plexu
ebv
multianalyt
diagnost
serolog
test
kit
use
detect
presenc
absenc
igg
igm
antibodi
human
blood
serum
use
diagnosi
viru
infect
infecti
mononucleosi
randox
evid
biochip
array
system
perform
miniatur
multiplex
immunoassay
macroarray
format
contain
featur
chemiluminesc
use
readout
fulli
autom
clinic
biochip
analyz
screen
patient
sampl
varieti
marker
specif
fertil
cardiac
diseas
tumor
cytokin
growth
factor
cell
adhes
molecul
thyroid
function
drug
abus
compani
drug
abus
panel
receiv
fda
clearanc
assay
current
evalu
fda
envisag
grow
number
biomark
defin
appli
diagnost
test
futur
goal
requir
appropri
qualiti
control
put
place
releas
nonrequest
test
data
handl
diagnost
result
implement
regul
biomark
pattern
provid
individu
inform
provid
support
clinician
diagnosi
select
optim
therapi
multiplex
protein
assay
becom
wide
accept
implement
differ
diagnost
area
advanc
protein
microarray
technolog
enabl
clinician
use
drop
blood
screen
patient
relev
patholog
inform
doctor
offic
particular
drug
prescrib
fda
critic
path
initi
innov
medicin
initi
partnership
european
commun
european
feder
pharmaceut
industri
associ
strategi
support
develop
biomark
assay
tradit
diagnost
purpos
support
drugdevelop
process
publicli
support
effort
set
back
collabor
compani
polici
maker
research
institut
hospit
activ
potenti
acceler
develop
protein
microarray
diagnost
purpos
lead
person
medicin
becom
realiti
nevertheless
proof
requir
medic
need
exist
diagnost
protein
array
provid
therapeut
relev
result
gener
overal
cost
reduct
array
final
fulfil
high
expect
rais
abbrevi
fppm
forwardphas
protein
microarray
rppm
reversedphas
protein
microarray
cancer
antigen
egfr
epiderm
growth
factor
receptor
apo
apolipoprotein
macrophag
inhibitori
protein
structurespecif
recognit
protein
sar
sever
acut
respiratori
syndrom
egf
epitheli
growth
factor
hgf
hepatocyt
growth
factor
rant
regul
upon
activ
normal
texpress
presum
secret
vascular
cell
adhes
molecul
monocyt
chemoattract
protein
ibd
inflammatori
bowel
diseas
interferon
protein
fda
food
drug
administr
anca
antineutrophil
cytoplasm
antibodi
